Haematopoietic stem cell transplantation (HSCT) represents the treatment of choice for severe bone marrow failure in patients with Fanconi anaemia (FA). When the donor is a compatible relative, the chance of being cured with an allograft is in the order of 70%. However, for FA children lacking an HLA-identical sibling, the results of HSCT from an alternative donor are less satisfactory because of a higher risk of graft rejection, graft-versushost-disease (GVHD) and regimen-related toxicity. We report on a 12-year-old girl with FA, who was treated by T-cell-depleted (TCD) peripheral blood HSCT from her haploidentical uncle, using a novel fludarabine-based preparative regimen without radiation. She had rapid engraftment with no toxicity and no GVHD. Progressive recovery of both numbers of lymphocyte and of proliferative response to polyclonal activators occurred over time. At 18 months after transplantation, she is well with 100% donor chimerism and has recovered normal immune function.
Introduction
Fanconi anaemia (FA) is an autosomal recessive disorder characterised by chromosomal fragility, a variety of congenital abnormalities, progressive bone marrow failure and marked propensity to develop malignancies. 1 Haematological complications develop in virtually all cases and represent the main cause of death in 81% of FA patients before the age of 40 years. 2 Haematopoietic stem cell transplantation (HSCT) is the only curative approach, 3, 4 and excellent results have been reported when the donor is an HLA-identical sibling. Unfortunately, the majority of FA patients do not have a healthy HLA-identical relative.
To date, successful outcome for HSCT in FA patients from unrelated donors has been reported to be in the range 29-43%, 5, 6 graft rejection, high incidence of graft-versushost disease (GVHD) and regimen-related toxicity being the main cause of treatment failure. In the context of unrelated HSCT, designing a suitable conditioning regimen has been difficult because of increased sensitivity of FA cells to both DNA crosslinking agents 7 and radiation. 8 Investigators are still searching for the 'ideal' preparative regimen, able to reduce the risk of organ toxicity while ensuring a high level of engraftment with a low risk of GVHD. The best results have been observed with cyclophosphamide (CY) 40 mg/kg, rabbit antithymocyte globulin (ATG) and total body irradiation 450 cGy. 5 However, even with this regimen, graft rejection and grades II-IV acute GVHD rates of 30 and 50%, respectively, have been reported. Data about transplants from related HLA-mismatched donors are scarce and the reported outcome is even worse than that of allograft from unrelated volunteers. 3, [9] [10] [11] Recently, Boulad et al 10 successfully performed a T-celldepleted (TCD) related HLA-mismatched HSCT using a fludarabine (Flu)-based preparative regimen with radiation (450 cGy) in an FA patient who rejected the first allograft. Likewise, Elhasid et al 11 reported on a 10-year-old girl who was prepared with a Flu-based regimen and was given a second successful transplant from her haploidentical father following graft rejection of the first allograft performed using the HLA-disparate mother as donor. We describe another FA patient who was also successfully treated with a TCD haploidentical allograft, after a Flu-based preparative regimen, which, however, did not include radiotherapy.
Case report
An 8-year-old Caucasian girl was noted to have pallor, listlessness and easy bruising. The parents were first-degree relatives, without familial history of haematological disorders. She was found to have microcephaly, micrognatia and micropthalmia. No abnormality of the radius was observed. Full blood cell count showed haemoglobin 6.5 g/ dl, white blood cell count 3.2 Â 10 9 /l (absolute neutrophil count 1.0 Â 10 9 /l) and platelet count 12 Â 10 9 /l. Foetal haemoglobin was 10%. Bone marrow aspirate showed three-linear hypoplasia and in vitro culture of committed progenitors documented a reduced colony growth pattern (data not shown). Chromosomal breakage studies, including the mitomycin C and diepoxy butane (DEB) tests, led to a diagnosis of FA. Treatment with androgens and haematopoietic growth factors was started, but it did not produce any appreciable results. No HLA-compatible family donor was available. Since pancytopenia worsened over time, the search for a suitable marrow or cord blood unrelated donor was begun, but it was unsuccessful. Therefore, consideration was given to using a non-HLAidentical family donor. At 4 years after initial diagnosis, the patient started conditioning for three-loci HLA-mismatched peripheral blood HSCT from her uncle. This donor, who was HLA identical with the patient's father, was chosen in view of the detection of HCV-RNA in the father and of the limited body size of the mother. Complete evaluation of patient liver, renal and respiratory function, performed before transplantation, showed normal parameters. Neither renal nor cardiac anomalies were found at ultrasonography. The patient received Flu (40 mg/m 2 ) from day À6 to day À3, CY (10 mg/kg) from day À6 to day À3 and rabbit ATG (3.75 mg/kg/day) from day À6 to day À3. The donor received G-CSF at a dosage of 8 mg/kg twice daily for six consecutive days to mobilise haematopoietic stem cells and underwent leukapheresis on days 4, 5 and 6. Donor stem cells were depleted of T cells by positive selection of CD34+ cells using the Clinimacs device (Miltenyi Biotec, Italy). On day 0, the patient was given 25 Â 10 6 CD34+ cells/kg with 1 Â 10 4 CD3+ cells/kg. Infection prophylaxis consisted of cotrimoxazole, acyclovir, amphotericin B, penicillin and intravenous immunoglobulin. No further prophylaxis for GVHD was employed. Haematopoietic and lymphoid engraftment were documented by studying the genetic polymorphism of a variable number of tandem repeat short DNA sequences (VNTRs). The clinical post-transplant course was initially unremarkable, complicated only by grade I-II mucositis. Neutrophil engraftment (40.5 Â 10 9 /l) occurred on day 12, whereas a self-sustained platelet count greater than 20 Â 10 9 /l was reached on day 18. At 1 month after allograft, the patient experienced an episode of seizures, associated with mild fever. A cerebral CT scan urgently performed, disclosed a small area of calcification surrounded by oedema in the left temporal lobe. Suspecting toxoplasma infection (subsequently confirmed by serologic tests), a specific therapy with sulphadiazine and pyrimethamine was started and successfully continued for 40 days until a second cerebral CT showed complete resolution of the lesion. Pretransplant donor and recipient toxoplasma serology was positive, this latter finding being proved to be the most important risk factor for reactivation of infection in HSCT recipients. 12 No neurologic sequel persisted over time. She was discharged on day +60. At 3 months after allograft, she developed asymptomatic antigenemia for HCMV. She received a full course of ganciclovir with negativisation of antigenemia within 1 month of starting therapy. Polymerase chain reaction test monitoring of HHV6-DNA, performed every week, was always negative. At 5 months after HSCT, the patient, although asymptomatic, was found to be positive for 1000 genome copies of EBV DNA/ 10 5 on two sequential occasions. Since an increment of values of EBV DNA is considered to be predictive for a high risk of developing symptomatic EBV infection, 13 the girl received two doses of 2 Â 10 7 EBV-specific CTL/m 2 generated according to a method previously described. 14 In detail, EBV-specific CTLs were prepared from fresh donor PBMCs, plated in X-VIVO 20 medium (BioWhittaker, Walkersville, MD, USA) with 2% autologous plasma at 2 Â 10 6 cells per well, and stimulated with irradiated autologous B lymphoblastoid cell lines (B-LCL) at a responder/stimulator (R:S) ratio of 40:1. After 10 days, cultures were restimulated with irradiated autologous B-LCL at an R:S ratio of 4:1. Starting on day 14, 20 U/ml recombinant interleukin 2 (rIL-2; Hoffman-La Roche, Basel, Switzerland) was added to the wells, and the cultures were subsequently restimulated weekly with irradiated autologous B-LCL in the presence of rIL-2. T cells were examined for EBV specificity in a standard 51 Cr-release assay against a panel of targets, including recipient B-LCL and phytohaemagglutinin (PHA) blasts, HLA-mismatched allogeneic B-LCL and PHA blasts, and the lymphokineactivated killer-permissive Daudi cell line. No other concomitant antiviral drug therapy was delivered to the patient. In 6 weeks, EBV DNA levels became undetectable; no symptoms and signs of GVHD were observed. Molecular analysis of VNTRs DNA sequences on peripheral blood cells at day +20 and 3, 6, 8 and 12 months after HSCT showed 100% donor chimerism. At 18 months after transplantation, the patient is well, with normal blood cell counts (WBC 7.1 Â 10 9 /l; Hb 14.2 g/dl; platelets 256 Â 10 9 /l) and a Karnofsky score of 100%.
The patient's immune function was serially monitored over time; results are reported in detail in Table 2 . The patient experienced profound impairment of immune function during the first 6 months after the allograft. Progressive recovery of both numbers of lymphocyte and of proliferative response to polyclonal activators occurred over time. Response to nominal antigens (ie Candida albicans and HCMV) was observed only 1 year after HSCT (data not shown). Detectable NK activity was already present after the first few months following transplantation (see Table 2 for further details).
Discussion
Children with FA, having a matched family donor, and conditioned with the traditional regimen of low-dose CY (20 mg/kg) and thoraco-abdominal irradiation, generally engraft fully with few peritransplant complications. 3, 4, 15 These children have been reported to have approximately a 70% overall survival, an 8% risk of rejection and a 45% risk of developing acute and/or chronic GVHD. 3, 4, 15 Unfortunately, less than 25% of FA patients have a suitable HLA-identical sibling donor. For the remaining patients, results of transplantation from alternative donors have been reported to be poorer, graft rejection, regimen-related toxicity and high risk of GVHD being the greatest obstacles to successful outcome. 4, 5 In particular, for these patients, the 'ideal' preparative regimen capable of reducing the risk of organ toxicity, while ensuring a high level of engraftment and a low risk of GVHD, is still to be identified.
Flu-based conditioning regimens, capable of intense T-cell immunosuppression, have been reported to lead to early, stable engraftment with minimal toxicity in patients with several either malignant or nonmalignant diseases unable to tolerate conventional myeloablative therapy. 16, 17 FA patients are natural candidates for nonmyeloablative stem cell transplantation after a Flu-containing regimen because of their cellular hypersensitivity to DNA crosslinking, and reports on the use of Flu as part of the conditioning regimen in FA children transplanted from a compatible sibling have been recently published. 18, 19 Many transplants for FA children with an unrelated donor are being performed with some forms of TCD, which offer the potential for prevention of GVHD without the morbidity associated with the use of immunosuppressive drugs such as methotrexate and cyclosporine. On the other hand, TCD in unrelated donor HSCT was associated with a higher incidence of graft rejection when compared with conventional allograft. 4 The case we present suggests that adopting a low-intensity, nonmyeloablative but highly immunosuppressive, regimen consisting of Flu, low-dose CY and ATG in the setting of alternative HSCT can afford stable, early and long-lasting engraftment without undue toxicity. Our report provides support to the finding recently reported by Wagner et al, 20 who found that FA patients given a TCD allograft from an unrelated donor after a Flu-based regimen were those with the highest chance of engraftment. It is also reasonable to speculate that, in our case, the high number of cells infused significantly contributed to the successful outcome for our patient, since a high number of CD34+ cells infused has been documented to be crucial for obtaining engraftment when an HLA disparity between donor and recipient exists. 21 A noteworthy aspect regarding the transplant procedure was the exclusion of radiotherapy from the preparative regimen. FA patients have been documented to be at high risk for the development of solid tumours, such as squamous cell carcinoma, years after HSCT. 22 Chronic GVHD and irradiation (total body or thoraco-abdominal) as part of the conditioning regimen were risk factors for the development of the secondary tumours in FA patients given an allograft. 22 Since radiation itself has been recently reported to promote the development of chronic GVHD in children, 23 the use of a nonradiotherapy containing regimen could also have the advantage of reducing the risk of developing late malignancies in patients with FA surviving after HSCT. Moreover, this type of preparative regimen could also prevent the occurrence of growth impairment and sterility, well-known long-term side effects of radiation. 24 Adoptive immunotherapy with transfer of lymphocytes or EBV-specific CTLs of donor origin is effective as prophylaxis and/or treatment of EBV-related lymphoproliferative disorders in recipients of TCD HSCT. 25 In our case, infusion of EBV-specific CTLs led to a complete clearance of viral DNA without causing GVHD and it was followed by a significant increase of lymphocyte number and by an improvement of their function, this suggesting a favourable role of adoptive immunotherapy in accelerating immune reconstitution.
In conclusion, our successful case suggests that highly immune-suppressive regimens including Flu followed by infusion of a large number of TCD CD34+ cells from a partially matched relative may represent a feasible and efficacious approach to cure FA patients with lifethreatening aplastic anaemia, in whom either a related or an unrelated donor cannot be located. In these patients, 
